ProCE Banner Activity

Enhancing Care in Moderate to Severe Psoriasis: Treatment Selection, Medication Adherence, and Healthcare Disparities

Slideset Download

Download these slides for an expert review of novel therapies, improved adherence, and reducing health disparities in the management of moderate to severe psoriasis

Released: September 09, 2022

Expiration: September 08, 2023

Begin Activity

Share

Faculty

Steven Feldman

Steven Feldman, MD, PhD

Professor
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Melodie Young, MSN, RN, ANP-C

Melodie Young, MSN, RN, ANP-C,

Nurse Practitioner
Mindful Dermatology and Modern Research Associates
Dallas, Texas

Acknowledgement

This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte Corporation; Novartis Pharmaceuticals Corporation; and Sanofi and Regeneron Pharmaceuticals.

Disclosure

Steven Feldman, MD, PhD: consultant/speaker: AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Forte, Helsinn, Janssen, Leo, Lilly, Mylan, Novartis, Pfizer, Samsung, Sanofi, Sun, UCB, vTv Therapeutics, Voluntis; researcher: Galderma, Janssen, Lilly, Pfizer, Regeneron; stock/stock options: Sensal Health.

Melodie S. Young, MSN, RN, ANP-C: consultant/advisor/speaker: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Janssen, Leo, Lilly, Novartis, UCB.

Additional Information

Program Medium

This program has been made available online.